

Supplemental Table I. Summary of the changes made to previous guidelines

The following is a summary of the differences with the European Dermatology Forum/European Academy of Dermatology and Venereology guidelines.

- The following set of guidelines was revised to include diagnostic and management interventions for pemphigus vulgaris and pemphigus foliaceus only
 - The roles of general practitioners, nurse practitioners, and home care health nurses were defined
 - The titles *first-line* and *second-line adjuvants* were changed to *first-line corticosteroid-sparing agents* and *other corticosteroid-sparing agents*
 - Intravenous CD20 inhibitors were added as a first-line treatment recommendation for moderate-to-severe pemphigus
 - The following qualifying statement was added to the recommendation regarding analysis of thiopurine methyltransferase activity when azathioprine is considered: "in countries where genetic polymorphisms for decreased thiopurine methyltransferase activity levels are more common"
 - *In case of elevated risk* was removed as a qualifying statement with regard to checking a Quantiferon or purified protein derivative skin test to rule out tuberculosis prior to initiation of treatment
 - Statements of facts as opposed to recommendations were removed
-